Fomulation and Evaluation of Mouth Dissolving Tablets of Losartan Potassium to Enhancebioavailability

In the current work, the development and testing of losartan potassium mouth dissolving tablets (MDTs) are aimed at increasing the bioavailability and efficacy of losartan. Losartan potassium is an angiotensin II receptor blocker which is common in the management of hypertension, but which has the disadvantage of low oral bioavailability, owing to its high first-pass metabolism, and moderate solubility. In patients, especially during pediatric and geriatric age groups, traditional routes of administration of drugs cause delayed drug absorption and low compliance. To address these shortcomings, the direct compression technique was employed to formulate MDTs with appropriate excipients, such as superdisintegrants like sodium starch glycolate and crospovidone. Different formulations (F1- F6) were made and tested under pre-compression parameters such as angle of repose, bulk density and Carr index and Hausner ratio which suggested good flow characteristics. Post compression tests such as hardness, friability, weight change, and drug content revealed all the preparations were within the limits of the pharmacopoeial requirements. The optimized formulation was characterized by fast disintegration, high rate of dissolution and good mechanical strength. MDTs enable quicker release and absorption of drugs through the oral mucosa, which minimizes the first-pass metabolism and improves bioavailability. Also, they enhance compliance among patients as it does not require water and it is easily administered. Therefore, losartan potassium MDTs are a promising intervention in enhancing therapeutic outcomes in the management of hypertension.